Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592091290> ?p ?o ?g. }
- W2592091290 endingPage "23712" @default.
- W2592091290 startingPage "23702" @default.
- W2592091290 abstract "// Katarzyna J. Nytko 1, 2 , Ivo Grgic 1, 2 , Sabine Bender 1 , Janosch Ott 1 , Matthias Guckenberger 3 , Oliver Riesterer 2, 3 , Martin Pruschy 1, 2 1 Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland 2 Clinical Research Priority Program “Tumor Oxygenation”, Zurich, Switzerland 3 Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland Correspondence to: Martin Pruschy, email: martin.pruschy@usz.ch Keywords: evofosfamide, TH-302, hypoxia-activated prodrug, ionizing radiation, P450 oxidoreductase Received: June 29, 2016 Accepted: February 06, 2017 Published: February 28, 2017 ABSTRACT The promising treatment combination of ionizing radiation (IR) with a hypoxia-activated prodrug (HAP) is based on biological cooperation. Here we investigated the hypoxia-activated prodrug evofosfamide in combination with different treatment regimens of IR against lung A549- and head&neck UT-SCC-14-derived tumor xenografts. DNA damage-related endpoints and clonogenic cell survival of A549 and UT-SCC-14 carcinoma cells were probed under normoxia and hypoxia. Evofosfamide (TH-302) induced DNA-damage and a dose-dependent antiproliferative response in A549 cells on cellular pretreatment under hypoxia, and supra-additively reduced clonogenic survival in combination with IR. Concomitant treatment of A549-derived tumor xenografts with evofosfamide and fractionated irradiation induced the strongest treatment response in comparison to the corresponding neoadjuvant and adjuvant regimens. Adjuvant evofosfamide was more potent than concomitant and neoadjuvant evofosfamide when combined with a single high dose of IR. Hypoxic UT-SCC-14 cells and tumor xenografts thereof were resistant to evofosfamide alone and in combination with IR, most probably due to reduced P450 oxidoreductase expression, which might act as major predictive determinant of sensitivity to HAPs. In conclusion, evofosfamide with IR is a potent combined treatment modality against hypoxic tumors. However, the efficacy and the therapeutic outcome of this combined treatment modality is, as indicated here in preclinical tumor models, dependent on scheduling parameters and tumor type, which is most probably related to the status of respective HAP-activating oxidoreductases. Further biomarker development is necessary for the launch of successful clinical trials." @default.
- W2592091290 created "2017-03-16" @default.
- W2592091290 creator A5003634048 @default.
- W2592091290 creator A5023510680 @default.
- W2592091290 creator A5024678921 @default.
- W2592091290 creator A5044990086 @default.
- W2592091290 creator A5049984560 @default.
- W2592091290 creator A5061630297 @default.
- W2592091290 creator A5060437035 @default.
- W2592091290 date "2017-02-28" @default.
- W2592091290 modified "2023-10-16" @default.
- W2592091290 title "The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy" @default.
- W2592091290 cites W1605399277 @default.
- W2592091290 cites W1605765845 @default.
- W2592091290 cites W1768095788 @default.
- W2592091290 cites W1846584383 @default.
- W2592091290 cites W1965887310 @default.
- W2592091290 cites W1992322726 @default.
- W2592091290 cites W1997122877 @default.
- W2592091290 cites W2024903578 @default.
- W2592091290 cites W2041365708 @default.
- W2592091290 cites W2053662954 @default.
- W2592091290 cites W2054126150 @default.
- W2592091290 cites W2061137918 @default.
- W2592091290 cites W2064048784 @default.
- W2592091290 cites W2087565365 @default.
- W2592091290 cites W2092518988 @default.
- W2592091290 cites W2100525241 @default.
- W2592091290 cites W2104928951 @default.
- W2592091290 cites W2117120027 @default.
- W2592091290 cites W2118170166 @default.
- W2592091290 cites W2118384081 @default.
- W2592091290 cites W2118957304 @default.
- W2592091290 cites W2126669622 @default.
- W2592091290 cites W2148585456 @default.
- W2592091290 cites W2160407692 @default.
- W2592091290 cites W2165787535 @default.
- W2592091290 cites W2303515996 @default.
- W2592091290 cites W2518197193 @default.
- W2592091290 cites W3157127121 @default.
- W2592091290 doi "https://doi.org/10.18632/oncotarget.15784" @default.
- W2592091290 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5410338" @default.
- W2592091290 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28423594" @default.
- W2592091290 hasPublicationYear "2017" @default.
- W2592091290 type Work @default.
- W2592091290 sameAs 2592091290 @default.
- W2592091290 citedByCount "27" @default.
- W2592091290 countsByYear W25920912902017 @default.
- W2592091290 countsByYear W25920912902018 @default.
- W2592091290 countsByYear W25920912902019 @default.
- W2592091290 countsByYear W25920912902020 @default.
- W2592091290 countsByYear W25920912902021 @default.
- W2592091290 countsByYear W25920912902022 @default.
- W2592091290 countsByYear W25920912902023 @default.
- W2592091290 crossrefType "journal-article" @default.
- W2592091290 hasAuthorship W2592091290A5003634048 @default.
- W2592091290 hasAuthorship W2592091290A5023510680 @default.
- W2592091290 hasAuthorship W2592091290A5024678921 @default.
- W2592091290 hasAuthorship W2592091290A5044990086 @default.
- W2592091290 hasAuthorship W2592091290A5049984560 @default.
- W2592091290 hasAuthorship W2592091290A5060437035 @default.
- W2592091290 hasAuthorship W2592091290A5061630297 @default.
- W2592091290 hasBestOaLocation W25920912901 @default.
- W2592091290 hasConcept C108215921 @default.
- W2592091290 hasConcept C109316439 @default.
- W2592091290 hasConcept C117262875 @default.
- W2592091290 hasConcept C126322002 @default.
- W2592091290 hasConcept C178790620 @default.
- W2592091290 hasConcept C185592680 @default.
- W2592091290 hasConcept C190283241 @default.
- W2592091290 hasConcept C202751555 @default.
- W2592091290 hasConcept C2776313096 @default.
- W2592091290 hasConcept C2779081379 @default.
- W2592091290 hasConcept C502942594 @default.
- W2592091290 hasConcept C509974204 @default.
- W2592091290 hasConcept C540031477 @default.
- W2592091290 hasConcept C55493867 @default.
- W2592091290 hasConcept C71924100 @default.
- W2592091290 hasConcept C7836513 @default.
- W2592091290 hasConcept C98274493 @default.
- W2592091290 hasConceptScore W2592091290C108215921 @default.
- W2592091290 hasConceptScore W2592091290C109316439 @default.
- W2592091290 hasConceptScore W2592091290C117262875 @default.
- W2592091290 hasConceptScore W2592091290C126322002 @default.
- W2592091290 hasConceptScore W2592091290C178790620 @default.
- W2592091290 hasConceptScore W2592091290C185592680 @default.
- W2592091290 hasConceptScore W2592091290C190283241 @default.
- W2592091290 hasConceptScore W2592091290C202751555 @default.
- W2592091290 hasConceptScore W2592091290C2776313096 @default.
- W2592091290 hasConceptScore W2592091290C2779081379 @default.
- W2592091290 hasConceptScore W2592091290C502942594 @default.
- W2592091290 hasConceptScore W2592091290C509974204 @default.
- W2592091290 hasConceptScore W2592091290C540031477 @default.
- W2592091290 hasConceptScore W2592091290C55493867 @default.
- W2592091290 hasConceptScore W2592091290C71924100 @default.
- W2592091290 hasConceptScore W2592091290C7836513 @default.
- W2592091290 hasConceptScore W2592091290C98274493 @default.
- W2592091290 hasIssue "14" @default.